51Թ

subscribe

51Թlaunches new research centre for innovation in energy storage and conversion

Electrification of everything will dramatically increase demand for energy storage and conversion, from advanced batteries to green hydrogen and carbon-free fuels, highlighting need for accelerated innovation efforts

Published: 25 May 2021

Introducing the science world to a unique Quebec COVID-19 resource

PLOS ONE publishes foundational article on the Biobanque québécoise de la COVID-19 (BQC19)

Published: 20 May 2021

Major boost to brain research with new $4M grant to help advance the field of neuroscience

Congratulations to our 51ԹNeuroscience researchers for their role in the Brain Canada grant led by Dr. Yves de Koninck (Laval University): The Canadian Optogenetics and Vectorology Foundry. 51Թneuroscientists and other team members from across the country form a consortium of research sites that aims to accelerate the development and dissemination of optogenetic and viral tools.

Published: 13 Apr 2021

International platform for sharing cardiovascular data launched by euCanSHare

McGill's Professor Bartha Maria Knoppers to co-lead the work package on ethics and interoperability.

Published: 6 Apr 2021

Tri-Agency Research Data Management Policy

On March 15, Canada’s three federal research funding agencies—the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council (NSERC) and the Social Sciences and Humanities Research Council (SSHRC) launched the Tri-Agency Research Data Management Policy (“RDM Policy”).

Published: 31 Mar 2021

New Digital Research Services Team and Website

McGill’s researchers are increasingly reliant on the production, sharing and management of large amounts of data to generate knowledge. Regardless of the research discipline, scope and scale of the research activities, or technological proficiency, access to digital infrastructure has become a fundamental need.

Published: 30 Mar 2021

Government of Canada funds McGill research on contaminants in aquatic ecosystems

Microplastics are tiny pieces of plastic that are microscopic and up to 5 millimetres in size. 51Թresearch project aims to provide an understanding of how these contaminants end up in Canadian aquatic environments and what impacts they have. 

Published: 29 Mar 2021

51Թleads in urgent virus variant research network

Experts across Canada, including researchers at McGill, are working to understand the impact of COVID-19 virus variants of concern on the health of Canadians and our public health measures.

Published: 26 Mar 2021

51Թand Genome Canada announce new Canadian SARS-CoV-2 Data Portal

A Made-in-Canada data solution to support the Government of Canada Variants of Concern Strategy

Published: 23 Mar 2021

Professor Nancy Ross Appointed Vice-Principal, Research, at Queen’s University

After nearly 5 years as McGill’s Associate Vice-Principal, Research and Innovation (AVP-RI), Professor Nancy Ross is leaving 51Թto join Queen’s University as Vice-Principal, Research. She will begin her appointment on August 1, 2021.

Published: 17 Mar 2021

51Թto partner with CCRM in commercializing regenerative medicine

51Թ announced today it has concluded an agreement with the Centre for Commercialization of Regenerative Medicine (CCRM) to provide McGill-based startup companies with the benefit of CCRM’s market-leading business intelligence and experience.

Email address:
Published: 10 Mar 2021

$110M for Nine Innovative 51ԹResearch Projects

Read the story in the 51ԹReporter

Read the McGill news release

Published: 9 Mar 2021

Marc Rousseau joins 51Թas Director, Research Software

Research and Innovation and IT Services are pleased to welcome Marc Rousseau to the role of Director, Research Software / Directeur du Logiciel de Recherche. In this new role, Rousseau provides support and advice to the 51Թresearch community on software, from grant applications to the implementation of research activities.

Published: 25 Feb 2021

Diamond Therapeutics Signs Agreement with 51Թ for Research on Low-Dose LSD

TORONTO, Feb. 4, 2021 /CNW/ - Diamond Therapeutics Inc. ("Diamond"), a leading psychedelic drug development company focused on low-dose therapies for mental health, has entered into an agreement with 51Թ for the exclusive use of Dr. Gabriella Gobbi's groundbreaking studies with lysergic acid diethylamide (LSD), its mechanism of action on the brain, and its potential for use at low doses in the treatment of mental health disorders. 

Published: 4 Feb 2021

Four 51Թprojects receive SSHRC Partnership Engage Grants

SSHRC invests over $80k in new 51Թresearch projects through the Partnership Engage Grants competition, two of which are directly related to COVID-19 research.

Published: 28 Jan 2021

Pages

Back to top